quinta-feira, dezembro 23, 2004
FDA aprova nova formulação do Invirase
Reuters Health 20.12.04
The U.S. Food and Drug Administration (FDA) has granted approval to a more potent formulation of Roche AG's HIV drug Invirase (saquinavir), meaning that patients will not need to take as many of the pills.
The FDA approved the drug in a 500-mg formulation, cutting the daily pill requirement from 5 to 2, Roche said in a statement on Monday.
Invirase, which is not among the Swiss drugmaker's top 20 products, was launched in 1995 and was the first HIV protease inhibitor on the market.
The U.S. Food and Drug Administration (FDA) has granted approval to a more potent formulation of Roche AG's HIV drug Invirase (saquinavir), meaning that patients will not need to take as many of the pills.
The FDA approved the drug in a 500-mg formulation, cutting the daily pill requirement from 5 to 2, Roche said in a statement on Monday.
Invirase, which is not among the Swiss drugmaker's top 20 products, was launched in 1995 and was the first HIV protease inhibitor on the market.
